Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ATXS : 12.98 (+0.62%)
TCBX : 39.89 (+0.89%)
RNA : 72.18 (+0.06%)
FSUN : 38.54 (+0.21%)
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

ATXS : 12.98 (+0.62%)
TCBX : 39.89 (+0.89%)
RNA : 72.18 (+0.06%)
FSUN : 38.54 (+0.21%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

TCBX : 39.89 (+0.89%)
RNA : 72.18 (+0.06%)
FIZN : 71.3000 (-6.18%)
WTRG : 38.57 (+0.36%)
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 72.18 (+0.06%)
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company...

RNA : 72.18 (+0.06%)
Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

RNA : 72.18 (+0.06%)
PLYM : 21.90 (+0.14%)
WTRG : 38.57 (+0.36%)
Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

JAMF : 12.99 (-0.08%)
RNA : 72.18 (+0.06%)
AWK : 131.28 (+0.41%)
Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis....

RNA : 72.18 (+0.06%)
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

RNA : 72.18 (+0.06%)
S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus

December S&P 500 E-Mini futures (ESZ25) are trending down -0.02% this morning, taking a breather after a record-breaking rally, while investors await the start of the Federal Reserve’s two-day policy...

PYPL : 60.04 (+1.06%)
NVDA : 188.61 (-0.32%)
NOVN.Z.IX : 110.100 (+1.33%)
MP : 54.54 (+0.61%)
RNA : 72.18 (+0.06%)
BNP.FP : 80.520 (-0.11%)
NXPI : 225.26 (-0.32%)
USAR : 14.53 (+2.98%)
RMBS : 94.48 (+0.31%)
CAP.FP : 141.650 (+0.18%)
UNH : 327.58 (+0.86%)
NDX1.D.DX : 28.900 (-1.10%)

Barchart Exclusives

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?
As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar